Circulative biomarkers as predictors of cardiovascular events in patients after treatment of Hodgkin lymphoma

Authors

DOI:

https://doi.org/10.14739/2409-2932.2017.3.113558

Keywords:

NT-proBNP, VE-cadherin, galectin-3, Hodgkin lymphoma, prognosis

Abstract

Aim. Nature development of lymphoma associates with increased risk of cardiovascular diseases. We aimed to evaluate the prognostic value of circulating NT-proBNP, galectin-3, and VE-cadherin in survivors of Hodgkin lymphoma.

Methods: Surveys were given to Hodgkin lymphoma survivors who reached at list partial response after treatment. Observation period was up to 3 years. ELISA method for measurements of circulating level of biomarkers was used.

Results: During observation period progression of Hodgkin lymphoma was proved in 8 patients, 4 persons were excluded for poor follow-up. Thirty four cumulative clinical events occurred in 11 patients (55%) within the follow-up, with their distribution being as follows: 2 cardiovascular deaths, 16 cardiac arrhythmias, 6 cardiac ischemic events, 1 stroke, 4 chronic heart failures and 5 hospital admissions for cardiovascular reasons. 4 deaths were not related with cardiovascular pathology or cardiovascular reasons.

Circulating level of NT-proBNP in patients without cardiovascular events and with cardiovascular events were 5.81 pg/ml (95% confidence interval [CI] = 3.21-8.41 pg/ml) and 12.74 pg/ml (95 % CI = 6.47-18.94 pg/ml) (р=0.072). In patients without cardiovascular events circulating level of galectin-3 was 5.91 pg/ml (95% confidence interval [CI] = 4.18-7.03 pg/ml) and in patients with cardiovascular events circulating level of galectin-3 was 14.33 pg/ml (95% CI = 5.99-16.18 pg/ml) (р=0.01). Circulating level of VE-cadherin in patients without cardiovascular events and with cardiovascular events were 0.40 pg/ml (95% confidence interval [CI] = 0.31-0.54 pg/ml) and 0.99 pg/ml (95% CI = 0.70-1.15 pg/ml) (р=0.02)

In multivariate logistic regression circulating NT-proBNP independently predicted cumulative cardiovascular events (odds ratio [OR] = 1,179; 95% CI = 1,043–1,334; р = 0.008) within 3 years of observation period.

Conclusion: Among patients after treatment of Hodgkin lymphoma increased circulating NT-proBNP may associate with increased cumulative cardiovascular events during 3 years.

References

  1. Cavallaro, U., Leibner, S., & Dejana, E. (2006) Endothelial cadherins and tumor angiogenesis. Exp. Cell Res., 312(5), 659–667. doi: 10.1016/j.yexcr.2005.09.019.
  2. Falcone, C., Lucibello, S., Mazzucchelli, I., Bozzini, S., D'Angelo, A., Schirinzi, S., et al. (2011) Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int. J. Immunopathol. Pharmacol, 24(4), 905–913. doi: 10.1177/039463201102400409.
  3. Favier, O., Heutte, N., Stamatoullas-Bastard, A., Carde, P., Van't Veer, M. B., Aleman, B. M., et al. (2009) European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA) Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer, 115(8), 1680–1691. doi: 10.1002/cncr.24178.
  4. Gavard, J. (2013) Endothelial permeability and VE-cadherin: A wacky comradeship. Cell Adh. Migr., 7(6), 55–461. doi: 10.4161/cam.27330.
  5. Gumbiner, B. M. (2005) Regulation of cadherin-mediated adhesion in morphogenesis. Nature Rev. Mol. Cell Biol., 6(8), 622–634. doi: 10.1038/nrm1699.
  6. Jarolim, P. (2014) Overview of cardiac markers in heart disease. Clin. Lab. Med., 34, 1–14. doi: 10.1016/j.cll.2013.11.005.
  7. Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., et al. (2016) Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N. Engl. J. Med., 374(25), 2419–2429. doi: 10.1056/NEJMoa1510093.
  8. Meijers, W. C., van der Velde, A. R., & de Boer, R. A. (2014) The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure. Expert. Rev. Mol. Diagn, 14, 257–266. doi: 10.1586/14737159.2014.892421.
  9. Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., et al. (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N. Engl. J. Med., 372(17), 1598–1607. doi: 10.1056/NEJMoa1408648.
  10. Sivkovich, S. O., & Kysel'ova, O. A. (2012) Diagnostics, prognosis factors, and treatment of malignant lymphoproliferative disease. Hodgkin Disease. Lik. Sprava, 1–2, 56–63.
  11. van Nimwegen, F. A., Schaapveld, M., Janus, C. P., Krol, A. D., Petersen, E. J., Raemaekers, J. M. et al. (2014) Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern. Med., 175(6), 1007–1017. doi: 10.1001/jamainternmed.2015.1180.
  12. Vandyke, K., Chow, A. W., Williams, S. A, To, L. B., & Zannettino, A. C. (2013) Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. Br. J. Haematol., 161(4), 499–507. doi: 10.1111/bjh.12280.

Downloads

How to Cite

1.
Samura BB. Circulative biomarkers as predictors of cardiovascular events in patients after treatment of Hodgkin lymphoma. Current issues in pharmacy and medicine: science and practice [Internet]. 2017Nov.1 [cited 2026Jun.26];(3). Available from: https://pharmed.zsmu.edu.ua/article/view/113558

Issue

No. 3 (2017)

Section

Experimental and clinical pharmacology

License

Authors who publish with this journal retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
 Лицензия Creative Commons